Director Jonathan Bendheim filed a Form 4 with the SEC on August 10, 2026, reporting the acquisition of 2,716 restricted stock units of Phibro Animal Health Corp (NASDAQ: PAHC) on August 6, 2026.

Key Highlights

  • Grant date: August 6, 2026, with 2,716 Class A Common Stock RSUs acquired at a price of $0.
  • Vesting schedule: RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to continued service through each vesting date.
  • Post-transaction ownership: Following the transaction, Bendheim directly holds 5,984 shares of Class A Common Stock.
  • Security type: Each RSU represents a contingent right to receive one share of Class A Common Stock.
  • Role: Jonathan Bendheim is identified in the filing as a Director of Phibro Animal Health Corp.

Jonathan Bendheim RSU Award Details at Phibro Animal Health

According to the filing, Director Jonathan Bendheim acquired 2,716 restricted stock units of Phibro Animal Health Corp on August 6, 2026, at a price of $0. The transaction was recorded under transaction code "A" (acquisition) in Table I of the Form 4, covering non-derivative securities. The filing notes that the reported securities represent RSUs, each of which "represents a contingent right to receive one share of Class A Common Stock."

The filing discloses that the RSUs "vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to the Reporting Person's continued employment through the applicable vesting date." Following this transaction, Bendheim's direct beneficial ownership of Class A Common Stock stands at 5,984 shares, as reported in the filing.

The Form 4 was signed by Judith Weinstein as Attorney-in-Fact for Jonathan Bendheim and filed on August 10, 2026. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

The filing reports a single acquisition of 2,716 Class A Common Stock RSUs by Director Jonathan Bendheim at Phibro Animal Health Corp, granted at no cost on August 6, 2026, with a three-year ratable vesting schedule and resulting direct beneficial ownership of 5,984 shares.